📋 Indications & Clinical Dosage
*Initial treatment of advanced B-cell chronic lymphocytic leukaemia (CLL), First-line treatment in patients with sufficient bone-marrow reserves:*
BY IV INJ: Adult: 50 mg daily for 5 days every 28 days, usually givenfor 6 cycles. See product literature.
Children: Not recommended.
⚠️ Precautions & Warnings
Use with caution in renal insufficiency, fever, documented infection or pre-existing hematological disorder or CNS disorders or peripheral neuropathy. Increased susceptibility to skin cancer, worsening of existing skin cancer
⚠️ Adverse Reactions / Side Effects
Acutemyeloid, leukaemia,anorexia, chills, cough, diarrhoea, fever, immunosuppression, malaise, myelodysplastic syndrome, myelosupression, oedema, peripheral neuropathy, pneumonia, rash, visualdisturbances, weakness, autoimmune disorder, confusion, fibrosis,haemorrhage, immune-mediated haemolytic anaemia,neutropenia, pneumonitis, pulmonary toxicity, thrombocytopenia, alopecia, bone-marrow suppression, extravasation, haemorrhagic cystitis, hyperuricaemia, nausea, oral mucositis, thromboembolism, tumourlysis syndrome, vomiting. Rare: Agitation, arrhythmia, blindness, coma, heart failure, optic neuropathy, seizures, skin cancer, Stevens-
Johnson syndrome, toxic epidermal necrolysis
🧪 Compatibility & Storage Stability
Compatibility: Stable in D5W, NS, SWFI
Stability & Storage: Store intact vials under refrigeration at 2C-8C. Reconstituted vials are stable for 16 days at room temperature of 15C-30C.